Lorus Therapeutics Stock Rating Upgraded by Zacks (LRUSF)
Lorus Therapeutics (NASDAQ:LRUSF) traded up 0.02% on Thursday, hitting $0.502. The stock had a trading volume of 83,885 shares. Lorus Therapeutics has a 52-week low of $0.16 and a 52-week high of $0.93. The stock has a 50-day moving average of $0.52 and a 200-day moving average of $0.52. The company’s market cap is $56.4 million.
Lorus Therapeutics (NASDAQ:LRUSF) last announced its earnings results on Friday, April 11th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.02. On average, analysts predict that Lorus Therapeutics will post $-0.07 earnings per share for the current fiscal year.
Several other analysts have also recently commented on the stock. Analysts at Cormark initiated coverage on shares of Lorus Therapeutics in a research note on Thursday, February 27th. They set a “buy” rating on the stock. Analysts at Roth Capital initiated coverage on shares of Lorus Therapeutics in a research note on Thursday, February 13th. They set a “buy” rating on the stock.
Lorus Therapeutics Inc (NASDAQ:LRUSF) is a life sciences company.
To view Zacks’ full report, visit Zacks’ official website.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.